Compare BMRC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMRC | RZLT |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.4M | 420.8M |
| IPO Year | 2007 | 2011 |
| Metric | BMRC | RZLT |
|---|---|---|
| Price | $26.78 | $4.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.67 | $9.67 |
| AVG Volume (30 Days) | 137.9K | ★ 1.4M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ 1.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $391.81 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $1.07 |
| 52 Week High | $30.92 | $11.46 |
| Indicator | BMRC | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 51.35 |
| Support Level | $25.14 | $4.48 |
| Resistance Level | $27.09 | $5.36 |
| Average True Range (ATR) | 0.70 | 0.27 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 29.51 | 34.31 |
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.